TOMA Biosciences holds U.S. patent for their innovative sample preparation process and next-generation sequencing technology — including their simple, highly efficient, single-stranded library preparation method based on oligo selective sequencing.

Foster City, CA

TOMA Biosciences has received a U.S. patent for their unique DNA next-generation sequencing technology. The U.S. Patent and Trademark Office issued to TOMA the U.S. patent entitled “Direct Capture, Amplification and Sequencing of Target DNA Using Immobilized Primers.” The patent carries a term extending to 2032.

TOMA’s patent stakes a claim to their efficient and comprehensive methods for sample preparation and targeted DNA sequencing. It also covers the TOMA OS-Seq™ reagent kits that can be used to accurately detect and analyze both single- and double-stranded DNA for all alteration types.

“The sample preparation process for targeted capture DNA sequencing can be very labor intensive,” said Wolfgang Daum, President